United Services Automobile Association bought a new stake in shares of Vericel Corp (NASDAQ:VCEL) during the 2nd quarter, according to its most recent filing with the SEC. The firm bought 242,884 shares of the biotechnology company’s stock, valued at approximately $2,356,000. United Services Automobile Association owned 0.57% of Vericel as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in VCEL. Northern Trust Corp boosted its position in Vericel by 472.7% during the 2nd quarter. Northern Trust Corp now owns 432,542 shares of the biotechnology company’s stock valued at $4,196,000 after purchasing an additional 357,014 shares during the period. Bank of New York Mellon Corp boosted its position in Vericel by 4.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 132,888 shares of the biotechnology company’s stock valued at $1,289,000 after purchasing an additional 5,854 shares during the period. California Public Employees Retirement System boosted its position in Vericel by 26.9% during the 2nd quarter. California Public Employees Retirement System now owns 55,695 shares of the biotechnology company’s stock valued at $540,000 after purchasing an additional 11,795 shares during the period. Castleark Management LLC boosted its position in Vericel by 27.2% during the 2nd quarter. Castleark Management LLC now owns 720,585 shares of the biotechnology company’s stock valued at $6,990,000 after purchasing an additional 154,068 shares during the period. Finally, Granahan Investment Management Inc. MA acquired a new position in Vericel during the 2nd quarter valued at approximately $2,295,000. Institutional investors and hedge funds own 76.48% of the company’s stock.

Shares of VCEL stock opened at $11.87 on Friday. The company has a quick ratio of 7.48, a current ratio of 7.72 and a debt-to-equity ratio of 0.16. Vericel Corp has a 1 year low of $3.30 and a 1 year high of $15.29. The firm has a market cap of $604.58 million, a price-to-earnings ratio of -24.80 and a beta of 3.00.

Vericel (NASDAQ:VCEL) last announced its quarterly earnings results on Monday, August 6th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.12). Vericel had a negative return on equity of 37.86% and a negative net margin of 23.35%. The company had revenue of $19.01 million during the quarter, compared to analyst estimates of $18.51 million. Equities analysts expect that Vericel Corp will post -0.36 EPS for the current year.

In other Vericel news, CFO Gerard J. Michel sold 15,000 shares of the business’s stock in a transaction on Monday, October 15th. The stock was sold at an average price of $12.65, for a total transaction of $189,750.00. Following the completion of the transaction, the chief financial officer now owns 165,960 shares in the company, valued at approximately $2,099,394. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Steven C. Gilman sold 9,000 shares of the business’s stock in a transaction on Tuesday, September 4th. The stock was sold at an average price of $12.03, for a total value of $108,270.00. Following the transaction, the director now owns 9,000 shares of the company’s stock, valued at approximately $108,270. The disclosure for this sale can be found here. Insiders have sold a total of 114,000 shares of company stock valued at $1,609,770 in the last quarter. 4.70% of the stock is currently owned by insiders.

A number of research analysts recently issued reports on the company. BidaskClub lowered Vericel from a “buy” rating to a “hold” rating in a research report on Tuesday, June 26th. BTIG Research restated a “buy” rating and set a $17.00 price objective on shares of Vericel in a research report on Tuesday, August 7th. LADENBURG THALM/SH SH upgraded Vericel from a “neutral” rating to a “buy” rating in a research report on Monday, July 16th. Finally, Needham & Company LLC reduced their price objective on Vericel from $15.00 to $14.00 and set a “buy” rating for the company in a research report on Wednesday, August 8th. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $15.00.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies to repair and regenerate damaged tissues and organs. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Carticel, an autologous chondrocyte implant for the repair of symptomatic cartilage defects of the femoral condyle caused by acute or repetitive trauma in patients that have inadequate response to a prior arthroscopic or other surgical repair procedure.

Read More: Growth Stocks, What They Are, What They Are Not

Want to see what other hedge funds are holding VCEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vericel Corp (NASDAQ:VCEL).

Institutional Ownership by Quarter for Vericel (NASDAQ:VCEL)

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.